{"id":11935,"date":"2021-03-23T17:35:58","date_gmt":"2021-03-23T12:05:58","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11935"},"modified":"2021-07-24T12:58:19","modified_gmt":"2021-07-24T07:28:19","slug":"pharma-happenings-in-takeda-roche-az-evotec","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec","title":{"rendered":"Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega\u2019s Recognition; Roche&#8217;s Tecentriq Results in NSCLC"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f2979da1d7e\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f2979da1d7e\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec\/#Promega_Biotech_Iberica_Gains_Recognition_for_COVID-19_Response_in_Spain\" >Promega Biotech Ib\u00e9rica Gains Recognition for COVID-19 Response in Spain<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec\/#US_data_shows_AstraZeneca_COVID_vaccine_79_effective\" >US data shows AstraZeneca COVID vaccine 79% effective<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec\/#Evotec_Takeda_collaborates_for_RNA_targeting_drug_discovery\" >Evotec, Takeda collaborates for RNA targeting drug discovery&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec\/#Roches_Tecentriq_Yields_Positive_Results_in_NSCLC\" >Roche&#8217;s Tecentriq Yields Positive Results in NSCLC&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-promega-biotech-ib-rica-gains-recognition-for-covid-19-response-in-spain\"><span class=\"ez-toc-section\" id=\"Promega_Biotech_Iberica_Gains_Recognition_for_COVID-19_Response_in_Spain\"><\/span><strong>Promega Biotech Ib\u00e9rica Gains Recognition for COVID-19 Response in Spain<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Promega Biotech Ib\u00e9rica has been heralded as the business leader in Spain for its COVID-19 response. The company\u2019s innovative approach to deal with <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">COVID-19 <\/a>and pandemic has led La Raz\u00f3n, a daily newspaper based in Madrid, to felicitate the biotech company with a Madrid Community SME (small- and medium-sized business) Award for demonstrating adaptation and innovation to lead the pandemic recovery in Spain.\u00a0<\/p>\n\n\n\n<p>Promega Biotech Ib\u00e9rica is a branch of Promega Corporation, which is an American multinational biotechnology manufacturer of&nbsp; reagents, assays and benchtop instruments used to assist the scientists in their COVID-19 response.&nbsp;<\/p>\n\n\n\n<p>The company had scaled up the manufacturing process in order to support and provide the products in hospitals, clinical diagnostic laboratories and molecular diagnostic manufacturers to facilitate SARS-CoV-2 testing globally. Promega Biotech Ib\u00e9rica was recognized specifically for Best Research and Development in Diagnostic Trials for Health Care in 2020.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-us-data-shows-astrazeneca-covid-vaccine-79-effective\"><span class=\"ez-toc-section\" id=\"US_data_shows_AstraZeneca_COVID_vaccine_79_effective\"><\/span><strong>US data shows AstraZeneca COVID vaccine 79% effective<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The deal between AstraZeneca and the University of Oxford for the development and marketing of the COVID-19 vaccine has been looked upon as the most successful and promising one in the market.&nbsp;<\/p>\n\n\n\n<p>AZ reported that AZD1222 demonstrated an efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization in the US phase III trials. The trial investigated 32,449 participants and the efficacy was observed to be consistent across all ethnicities and ages. While in participants of the age 65 years or older, efficacy was reported 80%.<\/p>\n\n\n\n<p>However, the journey of the vaccine was not smooth at all. During the initial days of the phase III trial itself, the trials had to be halted owing to the reports of the patient developing symptoms similar to a serious spinal inflammatory disorder called transverse myelitis. Not a long time ago, the company faced a setback as several companies suspended the prescription of the vaccine because of the report of the development of blood clots due to the vaccine dosage.\u00a0<\/p>\n\n\n\n<p>Nevertheless, as the saying goes all\u2019s well that ends well, for AZ it seems to be a happy ending now as its vaccine is being deployed in several parts of the world.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-evotec-takeda-collaborates-for-rna-targeting-drug-discovery\"><span class=\"ez-toc-section\" id=\"Evotec_Takeda_collaborates_for_RNA_targeting_drug_discovery\"><\/span><strong>Evotec, Takeda collaborates for RNA targeting drug discovery&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Evotec has announced a multi-RNA target alliance with Takeda in its quest to discover and develop RNA targeting small molecule therapeutics. The FDA approval of Roche\u2019s Evrysdi, the very first entrant as a small molecule modulator for RNA in the market, has now spiked the interest of biopharma players to test the waters.&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<p>The duo plans to jointly identify and develop small molecules that will target a spectrum of RNA\u00a0 sequences that can be developed into potentially first-in-class therapeutics. In return, Evotec will be eligible to receive research funding, along with discovery, pre-clinical, clinical, commercial and sales milestone payments of up to USD 160 million per program.\u00a0 Evotec will also obtain tiered royalties on net sales of the products.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-roche-s-tecentriq-yields-positive-results-in-nsclc\"><span class=\"ez-toc-section\" id=\"Roches_Tecentriq_Yields_Positive_Results_in_NSCLC\"><\/span><strong>Roche&#8217;s Tecentriq Yields Positive Results in NSCLC&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Roche has announced that its checkpoint inhibitor Tecentriq (atezolizumab) has produced promising results in the phase III <strong>IMpower010 <\/strong>trial of the drug compared to best supportive care (BSC) in people with resectable early-stage lung cancer. The primary endpoint was disease-free survival (DFS) at the interim analysis.<\/p>\n\n\n\n<p>Tecentriq showed a statistically significant improvement in DFS as adjuvant therapy after surgery and chemotherapy in all randomized Stage II-IIIA populations with <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">non-small cell lung cancer <\/a>(NSCLC). There was a pronounced benefit in the PD-L1-positive population.<\/p>\n\n\n\n<p>With such promising results, Tecentriq has now been heralded as the first cancer immunotherapy that has helped diverse patient pool with resectable early lung cancer t=by improving their survival rate and preventing relapse.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Promega Biotech Ib\u00e9rica Gains Recognition for COVID-19 Response in Spain Promega Biotech Ib\u00e9rica has been heralded as the business leader in Spain for its COVID-19 response. The company\u2019s innovative approach to deal with COVID-19 and pandemic has led La Raz\u00f3n, a daily newspaper based in Madrid, to felicitate the biotech company with a Madrid Community [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11936,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[96,15648,6733,1111,2792],"industry":[17225],"therapeutic_areas":[17231,17228],"class_list":["post-11935","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-astrazeneca","tag-covid-19-vaccines","tag-non-small-cell-lung-cancer","tag-nsclc","tag-tecentriq","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AZ COVID-19 Vaccine US Trials; Roche&#039;s Tecentriq Results in NSCLC<\/title>\n<meta name=\"description\" content=\"Evotec, Takeda Deal; AZ COVID-19 Vaccine US Trials; Promega\u2019s Recognition; Roche&#039;s Tecentriq Results in NSCLC\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AZ COVID-19 Vaccine US Trials; Roche&#039;s Tecentriq Results in NSCLC\" \/>\n<meta property=\"og:description\" content=\"Evotec, Takeda Deal; AZ COVID-19 Vaccine US Trials; Promega\u2019s Recognition; Roche&#039;s Tecentriq Results in NSCLC\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-23T12:05:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/23173210\/Evotec-Takeda-Deal-AZ-COVID-Vaccine-US-Trials-Promega%E2%80%99s-Recognition-Roches-Tecentriq-Results-in-NSCLC.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AZ COVID-19 Vaccine US Trials; Roche's Tecentriq Results in NSCLC","description":"Evotec, Takeda Deal; AZ COVID-19 Vaccine US Trials; Promega\u2019s Recognition; Roche's Tecentriq Results in NSCLC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec","og_locale":"en_US","og_type":"article","og_title":"AZ COVID-19 Vaccine US Trials; Roche's Tecentriq Results in NSCLC","og_description":"Evotec, Takeda Deal; AZ COVID-19 Vaccine US Trials; Promega\u2019s Recognition; Roche's Tecentriq Results in NSCLC","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-03-23T12:05:58+00:00","article_modified_time":"2021-07-24T07:28:19+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/23173210\/Evotec-Takeda-Deal-AZ-COVID-Vaccine-US-Trials-Promega%E2%80%99s-Recognition-Roches-Tecentriq-Results-in-NSCLC.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec","name":"AZ COVID-19 Vaccine US Trials; Roche's Tecentriq Results in NSCLC","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/23173210\/Evotec-Takeda-Deal-AZ-COVID-Vaccine-US-Trials-Promega%E2%80%99s-Recognition-Roches-Tecentriq-Results-in-NSCLC.jpg","datePublished":"2021-03-23T12:05:58+00:00","dateModified":"2021-07-24T07:28:19+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Evotec, Takeda Deal; AZ COVID-19 Vaccine US Trials; Promega\u2019s Recognition; Roche's Tecentriq Results in NSCLC","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-in-takeda-roche-az-evotec#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/23173210\/Evotec-Takeda-Deal-AZ-COVID-Vaccine-US-Trials-Promega%E2%80%99s-Recognition-Roches-Tecentriq-Results-in-NSCLC.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/23173210\/Evotec-Takeda-Deal-AZ-COVID-Vaccine-US-Trials-Promega%E2%80%99s-Recognition-Roches-Tecentriq-Results-in-NSCLC.jpg","width":772,"height":482,"caption":"Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega\u2019s Recognition; Roche's Tecentriq Results in NSCLC"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/23173210\/Evotec-Takeda-Deal-AZ-COVID-Vaccine-US-Trials-Promega%E2%80%99s-Recognition-Roches-Tecentriq-Results-in-NSCLC-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Covid-19 vaccines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tecentriq<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Covid-19 vaccines<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">Tecentriq<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 23, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 23, 2021 5:35 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega\u2019s Recognition; Roche's Tecentriq Results in NSCLC","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11935"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11935\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11936"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11935"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11935"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}